Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel Group, Dose-finding Phase 2 Study to Compare the Safety of the Oral FXIa Inhibitor BAY2433334 to Apixaban in Patients With Atrial Fibrillation

NCT04218266 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04218266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04218266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel Group, Dose-finding Phase 2 Study to Compare the Safety of the Oral FXIa Inhibitor BAY2433334 to Apixaban in Patients With Atrial Fibrillation
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
January 30, 2020
Completion date
October 8, 2021
Enrollment
755 (actual)
Sites
93

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation (af)